YB-1 protein correlates with high-risk tumor characteristics and response to high dose chemotherapy in breast cancer.

被引：0
|
作者：
Gluz, O.
Harbeck, N.
Kates, R. E.
Schmitt, M.
Mengele, K.
Royer, H-D
Eckstein, N.
Svjetlana, M.
Ting, E.
Poremba, C.
Nitz, U.
Diallo-Danebrock, R.
机构：
[1] Univ Dusseldorf, D-4000 Dusseldorf, Germany
[2] Tech Univ, Munich, Germany
[3] Caesar Inst, Bonn, Germany
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S136 / S136
页数：1
相关论文
共 50 条
  • [41] High-dose versus conventional chemotherapy for relapsed breast cancer.
    Donnellan, P
    Dillon, P
    Hoey, S
    Baker, A
    Smith, M
    Cameron, D
    Leonard, R
    BRITISH JOURNAL OF CANCER, 1999, 80 : 12 - 12
  • [42] Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer
    Recchia, Francesco
    Candeloro, Giampiero
    Rosselli, Michele
    Bratta, Massimo
    Pasta, Vittorio
    D'Orazi, Valerio
    Fumagalli, Luca A.
    Rea, Silvio
    ANTICANCER RESEARCH, 2015, 35 (12) : 6847 - 6853
  • [43] High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study
    Weiss, RB
    Rifkin, RM
    Stewart, FM
    Theriault, RL
    Williams, LA
    Herman, AA
    Beveridge, RA
    LANCET, 2000, 355 (9208): : 999 - 1003
  • [44] High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer Reply
    Steenbruggen, Tessa G.
    Steggink, Lars C.
    Sonke, Gabe S.
    JAMA ONCOLOGY, 2020, 6 (08) : 1300 - 1300
  • [45] High-dose chemotherapy and hematopoietic stem cell rescue for metastatic and high-risk primary breast cancer
    Baynes, RD
    Klein, JL
    Dansey, RD
    Karanes, C
    Abella, E
    Akhtar, A
    Cassels, L
    Peters, WP
    BONE MARROW TRANSPLANTATION, 1998, 22 : S87 - S90
  • [46] Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer
    Malinovszky, K. M.
    Gould, A.
    Foster, E.
    Cameron, D.
    Humphreys, A.
    Crown, J.
    Leonard, R. C. F.
    BRITISH JOURNAL OF CANCER, 2006, 95 (12) : 1626 - 1631
  • [47] Dutch studies of high-dose chemotherapy with hematopoietic progenitor cell support in high-risk breast cancer
    Rodenhuis, S
    de Vries, EGE
    BONE MARROW TRANSPLANTATION, 1998, 22 : S91 - S92
  • [48] Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer
    K M Malinovszky
    A Gould
    E Foster
    D Cameron
    A Humphreys
    J Crown
    R C F Leonard
    British Journal of Cancer, 2006, 95 : 1626 - 1631
  • [49] The tumor immune microenvironment correlates with neoadjuvant chemotherapy response in high-grade serous ovarian cancer.
    Zhu, Lei
    Cao, Guangming
    Hua, Dingchao
    Cui, Lina
    Zhao, Xiaochen
    Wang, Shuzhen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17605 - E17605
  • [50] Should breast reconstruction be delayed in high-risk breast cancer patients (pts) receiving High-Dose Chemotherapy (HDC)?
    Petit, J
    Youssef, O
    Rjetjens, M
    D'Ambrosio, M
    Luini, A
    Massaron, S
    Vanazzi, A
    Martinelli, G
    BONE MARROW TRANSPLANTATION, 2001, 27 : S119 - S119
12345